Juliann M Mellin1, Sankaraleengam Alagapan1, Caroline Lustenberger1, Courtney E Lugo1, Morgan L Alexander1, John H Gilmore1, L Fredrik Jarskog1, Flavio Fröhlich2. 1. Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States. 2. Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States; Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States; Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States; Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States; Carolina Center for Neurostimulation, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States. Electronic address: flavio_frohlich@med.unc.edu.
Abstract
BACKGROUND: Approximately 30% of patients with schizophrenia experience auditory hallucinations that are refractory to antipsychotic medications. Here, we evaluated the feasibility and efficacy of transcranial alternating current stimulation (tACS) that we hypothesized would improve auditory hallucination symptoms by enhancing synchronization between the frontal and temporo-parietal areas of the left hemisphere. METHOD: 22 participants were randomized to one of three arms and received twice daily, 20 min sessions of sham, 10 Hz 2 mA peak-to-peak tACS, or 2 mAtDCS over the course of 5 consecutive days. Symptom improvement was assessed using the Auditory Hallucination Rating Scale (AHRS) as the primary outcome measure. The Positive and Negative Syndrome Scale (PANSS) and the Brief Assessment of Cognition in Schizophrenia (BACS) were secondary outcomes. RESULTS: Primary and secondary behavioral outcomes were not significantly different between the three arms. However, effect size analyses show that tACS had the greatest effect based on the auditory hallucinations scale for the week of stimulation (1.31 for tACS; 1.06 and 0.17, for sham and tDCS, respectively). Effect size analysis for the secondary outcomes revealed heterogeneous results across measures and stimulation conditions. CONCLUSIONS: To our knowledge, this is the first clinical trial of tACS for the treatment of symptoms of a psychiatric condition. Further studies with larger sample sizes are needed to better understand the effect of tACS on auditory hallucinations.
RCT Entities:
BACKGROUND: Approximately 30% of patients with schizophrenia experience auditory hallucinations that are refractory to antipsychotic medications. Here, we evaluated the feasibility and efficacy of transcranial alternating current stimulation (tACS) that we hypothesized would improve auditory hallucination symptoms by enhancing synchronization between the frontal and temporo-parietal areas of the left hemisphere. METHOD: 22 participants were randomized to one of three arms and received twice daily, 20 min sessions of sham, 10 Hz 2 mA peak-to-peak tACS, or 2 mA tDCS over the course of 5 consecutive days. Symptom improvement was assessed using the Auditory Hallucination Rating Scale (AHRS) as the primary outcome measure. The Positive and Negative Syndrome Scale (PANSS) and the Brief Assessment of Cognition in Schizophrenia (BACS) were secondary outcomes. RESULTS: Primary and secondary behavioral outcomes were not significantly different between the three arms. However, effect size analyses show that tACS had the greatest effect based on the auditory hallucinations scale for the week of stimulation (1.31 for tACS; 1.06 and 0.17, for sham and tDCS, respectively). Effect size analysis for the secondary outcomes revealed heterogeneous results across measures and stimulation conditions. CONCLUSIONS: To our knowledge, this is the first clinical trial of tACS for the treatment of symptoms of a psychiatric condition. Further studies with larger sample sizes are needed to better understand the effect of tACS on auditory hallucinations.
Authors: Michael R Goldstein; Michael J Peterson; Joseph L Sanguinetti; Giulio Tononi; Fabio Ferrarelli Journal: Schizophr Res Date: 2015-07-07 Impact factor: 4.939
Authors: Stephen L Schmidt; Apoorva K Iyengar; A Alban Foulser; Michael R Boyle; Flavio Fröhlich Journal: Brain Stimul Date: 2014-07-19 Impact factor: 8.955
Authors: R Ishii; K Shinosaki; Y Ikejiri; S Ukai; K Yamashita; M Iwase; Y Mizuno-Matsumoto; T Inouye; T Yoshimine; N Hirabuki; S E Robinson; M Takeda Journal: Neuroreport Date: 2000-09-28 Impact factor: 1.837
Authors: Udo Reulbach; Stefan Bleich; Christian Maihofner; Johannes Kornhuber; Wolfgang Sperling Journal: Neuropsychobiology Date: 2007-06-15 Impact factor: 2.328
Authors: Kate E Hoy; Sara L Arnold; Melanie R L Emonson; Zafiris J Daskalakis; Paul B Fitzgerald Journal: Schizophr Res Date: 2014-04-02 Impact factor: 4.939
Authors: Hyein Cho; Lais B Razza; Lucas Borrione; Marom Bikson; Leigh Charvet; Tracy A Dennis-Tiwary; Andre R Brunoni; Pedro Sudbrack-Oliveira Journal: Focus (Am Psychiatr Publ) Date: 2022-01-25
Authors: Julius Kricheldorff; Katharina Göke; Maximilian Kiebs; Florian H Kasten; Christoph S Herrmann; Karsten Witt; Rene Hurlemann Journal: Brain Sci Date: 2022-07-15
Authors: Sangtae Ahn; Juliann M Mellin; Sankaraleengam Alagapan; Morgan L Alexander; John H Gilmore; L Fredrik Jarskog; Flavio Fröhlich Journal: Neuroimage Date: 2018-10-24 Impact factor: 6.556
Authors: Stacey B Daughters; Jennifer Y Yi; Rachel D Phillips; Regina M Carelli; Flavio Fröhlich Journal: Drug Alcohol Depend Date: 2020-06-18 Impact factor: 4.492